Company / Gross Margin
Immuneering Corp Gross Margin History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
50.1%
FY2023
5-year range
44.6% / 50.1%
FY2021-FY2023
Trend
+12.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from 44.6% to 50.1% over the past 2 years.
Based on SEC 10-K filings.
50.1% in FY2023.
Improved from 44.6% to 50.1% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, gross margin increased 12.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | 50.1% | +12.5% |
| FY2022 | 44.6% | -0.1% |
| FY2021 | 44.6% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026